ALK and neuroblastoma: Genetic/proteomic aberrations such as MYCN, BIRC5, PHOX2B, and LIN28B, and molecular pathways alterations such as ALK signaling, MDM2, PI3K/Akt/mTOR and RAS-MAPK pathways, have potential to supplement traditional clinical risk stratification in NB [2].